Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Harald Balló et al.|Journal of Clinical Oncology|2017Cited by 83
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung CancerWolf Köster, Michael Ståhl, Andrea Heider et al.|Journal of Thoracic Oncology|2007Cited by 26
Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 StudyMathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Blood|2014Cited by 13
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)Mathias Rummel, Wolfram Brugger, Christina Balser et al.|Blood|2014Cited by 5
Phase-II-study with bendamustine / carboplatin in untreated patients with extensive disease small cell lung cancerW. Koester, Michael Ståhl, Georgios Stamatis et al.|Journal of Clinical Oncology|2004Cited by 3